Avita Medical (RCEL) vs Senseonics (SENS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Avita Medical (RCEL) has outperformed Senseonics (SENS) over the past year, gaining 312.1% versus a gain of 49.9%. Over five years, RCEL leads with a +10.8% price change compared with -87.6% for SENS. Avita Medical is the larger company by market cap ($495.0 million vs $439.3 million), about 1.1 times the size, while Senseonics is growing revenue faster (+56.9% vs +11.5%).
Avita Medical converts more of its revenue into profit, with a net margin of -67.8% versus -196.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RCEL | SENS |
|---|---|---|
| Share price | $15.62 | $8.02 |
| Market cap | $494.96M | $439.34M |
| 1-day change | -2.31% | -9.94% |
| YTD return | +352.75% | +45.29% |
| 1-year return | +312.14% | +49.91% |
| 5-year return | +10.78% | -87.59% |
| EPS (TTM) | $-1.17 | $-2.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $71.61M | $35.26M |
| Revenue growth (YoY) | +11.45% | +56.89% |
| Net income (latest FY) | $-48.59M | $-69.10M |
| Gross margin | 82.13% | 44.71% |
| Operating margin | -59.40% | -193.83% |
| Net margin | -67.85% | -195.99% |
| 52-week high | $18.43 | $13.98 |
| 52-week low | $3.22 | $4.79 |
| Distance from 52-week high | -15.25% | -42.62% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +32.46% | +88.03% |
| Average volume | 417.02K | 821.73K |
| Shares outstanding | 31.69M | 54.78M |
| Employees | 226 | 130 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RCEL has outperformed SENS by 262.2 percentage points over the past year.
- Avita Medical is more profitable, keeping -67.8 cents of every revenue dollar as net income versus -196.0 cents for Senseonics.
- Senseonics grew revenue faster in its latest fiscal year (+56.89% vs +11.45%).
About Avita Medical
RCEL stock →AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions.
Health Care · Medical/Dental Instruments · 226 employees
About Senseonics
SENS stock →Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management.
Health Care · Medical/Dental Instruments · 130 employees
RCEL vs SENS FAQ
Which is bigger, Avita Medical or Senseonics?
Avita Medical (RCEL) is larger, with a market capitalization of $494.96M compared with $439.34M for Senseonics (SENS).
Which stock has performed better over the past year, RCEL or SENS?
RCEL returned +312.14% over the past 12 months, compared with +49.91% for SENS (price return, excluding dividends). Past performance does not predict future results.
Are Avita Medical and Senseonics in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.